Stockscreener 앱 받기
1.6999
2.59%
-0.0401
Opko Health Inc 주식(OPK)의 최신 뉴스
Here's Why You Should Retain OPKO Health Stock in Your Portfolio - Yahoo Finance
Charles Schwab Investment Management Inc. Has $5.14 Million Stock Position in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Zacks Research Weighs in on OPKO Health FY2027 Earnings - MarketBeat
OPKO Health Insider Ups Holding During Year - Simply Wall St
Quote - OPKO Health, Inc.
HC Wainwright Reaffirms "Buy" Rating for OPKO Health (NASDAQ:OPK) - MarketBeat
Best Buy, Las Vegas Sands, Globalstar, Opko Health, Agilent: Stock Moves Unveiled - MSN
OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Buys 200,000 Shares - MarketBeat
PRESS RELEASE ISSUED FEBRUARY 4, 2000 - OPKO Health, Inc.
Q2 EPS Estimates for OPKO Health Increased by HC Wainwright - MarketBeat
Chairman & CEO of OPKO Health Phillip Frost Buys More Stock - Yahoo Finance
H.C. Wainwright maintains Buy on Opko Health, $3 target By Investing.com - Investing.com Canada
OPKO Health, Entera Bio Partner on Oral Dual Agonist GLP-1 - Contract Pharma
Forecasting The Future: 6 Analyst Projections For OPKO Health - Benzinga
Opko and Entera focus on oral care for obesity and metabolic disorders - Yahoo Finance
Opko Health, Entera Bio sign agreement for oral GLP-1/glucagon dual agonist peptide - BioWorld Online
OPKO and Entera Link Up to Advance First Oral GLP-1/Glucagon Drug Into Clinic - BioSpace
OPKO and Entera Bio partner on oral obesity treatment By Investing.com - Investing.com Australia
Essential Planning LLC. Makes New $506,000 Investment in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
OPKO And Entera Bio Team Up For Game-Changing Obesity Pill - Finimize
OPKO Health, Entera Bio Collaborate To Develop Oral Dual GLP-1/Glucagon Therapy For Obesity - Nasdaq
Labcorp Is Buying BioReference Health’s Cancer Testing Business for $192 Million - Dealbreaker
OPKO and Entera partner to develop obesity pill - Reuters
Opko Health, Entera Bio to Collaborate on Tablet for Obesity, Metabolic and Fibrotic Disorders - MarketWatch
Entera Bio Collaborates with OPKO for Oral GLP-1/Glucagon - TipRanks
OPKO, Entera to Co-Develop Oral GLP-1/Glucagon Therapy for Obesity -March 17, 2025 at 08:38 am EDT - Marketscreener.com
OPKO and Entera Bio partner on oral obesity treatment - Investing.com India
OPKO Health and Entera Bio Enter into Collaboration - GlobeNewswire
Revolutionary Oral GLP-1 Obesity Treatment: OPKO and Entera Join Forces to Challenge Injectable Market - StockTitan
OPKO Health (NASDAQ:OPK) Earns Buy Rating from HC Wainwright - MarketBeat
OPKO Health (NASDAQ:OPK) Given "Outperform" Rating at Barrington Research - MarketBeat
Labcorp Is Buying BioReference Health’s Cancer Testing Business for $192M - MedCity News
Labcorp is Set to Acquire Select Assets of BioReference Health of OPK - MSN
OPKO Health (NASDAQ:OPK) Shares Gap UpStill a Buy? - MarketBeat
Tesla Stock Is Reaching a Breaking Point, Analyst Says. Plus, Vertical Aerospace, OPKO Health, and More. - Barron's
Is OPKO Health, Inc. (OPK) The Best Stock Under $3 to Buy Now? - Insider Monkey
HC Wainwright Reiterates Buy Rating for OPKO Health (NASDAQ:OPK) - Defense World
OPKO Health (NASDAQ:OPK) Earns Outperform Rating from Barrington Research - Defense World
10 Best Stocks Under $3 to Buy Now - Insider Monkey
H.C. Wainwright maintains $3 target on Opko Health stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $3 target on Opko Health stock - Investing.com
0.54%
1.06%
자본화:
|
볼륨(24시간):